111 related articles for article (PubMed ID: 12552813)
21. [Immunological and virological efficacy against HBV chronic infection of the therapeutic vaccine composed of HBV core plus PreS1 in HBV transgenic mice].
Li MZ; Chen XC; Zhou BP; Le XH; Xu LM; Wang HS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):277-9. PubMed ID: 15340577
[TBL] [Abstract][Full Text] [Related]
22. Expression and characterization of cholera toxin B-pneumococcal surface adhesin A fusion protein in Escherichia coli: ability of CTB-PsaA to induce humoral immune response in mice.
Arêas AP; Oliveira ML; Miyaji EN; Leite LC; Aires KA; Dias WO; Ho PL
Biochem Biophys Res Commun; 2004 Aug; 321(1):192-6. PubMed ID: 15358234
[TBL] [Abstract][Full Text] [Related]
23. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
Matoba N; Geyer BC; Kilbourne J; Alfsen A; Bomsel M; Mor TS
Vaccine; 2006 Jun; 24(23):5047-55. PubMed ID: 16621185
[TBL] [Abstract][Full Text] [Related]
24. [Coexpression of the preS1(1-42) and the Core(1-144) antigen of HBV in E. coli].
Zhao Y; Zhan M
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Jun; 22(3):227-31. PubMed ID: 12903465
[TBL] [Abstract][Full Text] [Related]
25. Optimisation of secretion of recombinant HBsAg virus-like particles: Impact on the development of HIV-1/HBV bivalent vaccines.
Michel M; Lone YC; Centlivre M; Roux P; Wain-Hobson S; Sala M
Vaccine; 2007 Feb; 25(10):1901-11. PubMed ID: 17005303
[TBL] [Abstract][Full Text] [Related]
26. DNA vaccines prime CD8+ T cell responses to epitopes of viral antigens produced from overlapping reading frames of a single coding sequence.
Fissolo N; Riedl P; Reimann J; Schirmbeck R
Eur J Immunol; 2005 Jan; 35(1):117-27. PubMed ID: 15593127
[TBL] [Abstract][Full Text] [Related]
27. Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice.
Zhao W; Wu W; Xu X
Vaccine; 2007 Nov; 25(44):7664-73. PubMed ID: 17913305
[TBL] [Abstract][Full Text] [Related]
28. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
29. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally.
Jaganathan KS; Vyas SP
Vaccine; 2006 May; 24(19):4201-11. PubMed ID: 16446012
[TBL] [Abstract][Full Text] [Related]
30. [Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].
Zeng RH; Gong W; Fang XP; Zhang ZY; Mei XG
Sheng Wu Gong Cheng Xue Bao; 2005 Jul; 21(4):534-9. PubMed ID: 16176088
[TBL] [Abstract][Full Text] [Related]
31. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
32. Pentabody-mediated antigen delivery induces antigen-specific mucosal immune response.
Li S; Zheng W; Kuolee R; Hirama T; Henry M; Makvandi-Nejad S; Fjällman T; Chen W; Zhang J
Mol Immunol; 2009 May; 46(8-9):1718-26. PubMed ID: 19269688
[TBL] [Abstract][Full Text] [Related]
33. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine.
Isaka M; Komiya T; Takahashi M; Yasuda Y; Taniguchi T; Zhao Y; Matano K; Matsui H; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
Vaccine; 2004 Aug; 22(23-24):3061-8. PubMed ID: 15297056
[TBL] [Abstract][Full Text] [Related]
34. Biochemical and immunological characterization of the plant-derived candidate human immunodeficiency virus type 1 mucosal vaccine CTB-MPR.
Matoba N; Kajiura H; Cherni I; Doran JD; Bomsel M; Fujiyama K; Mor TS
Plant Biotechnol J; 2009 Feb; 7(2):129-45. PubMed ID: 19037902
[TBL] [Abstract][Full Text] [Related]
35. [Construction and expression of non-fusional expression vector of the multi-epitope gene of hepatitis B virus].
Luo LM; Xia H; Li ZL; Yu ZY; Liu SR; Li M
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Aug; 24(8):788-90. PubMed ID: 18687219
[TBL] [Abstract][Full Text] [Related]
36. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
Vietheer PT; Boo I; Drummer HE; Netter HJ
Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
[TBL] [Abstract][Full Text] [Related]
37. Cholera toxin B subunit modulation of mucosal vaccines for infectious and autoimmune diseases.
Langridge W; Dénes B; Fodor I
Curr Opin Investig Drugs; 2010 Aug; 11(8):919-28. PubMed ID: 20721834
[TBL] [Abstract][Full Text] [Related]
38. Induction of neutralizing antibodies by a tobacco chloroplast-derived vaccine based on a B cell epitope from canine parvovirus.
Molina A; Veramendi J; Hervás-Stubbs S
Virology; 2005 Nov; 342(2):266-75. PubMed ID: 16140352
[TBL] [Abstract][Full Text] [Related]
39. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
40. [The primary study on the anti-HBV effect of whole recombinant yeast].
Zeng Y; Cai DC; Peng ML; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2003 Dec; 11(12):728-30. PubMed ID: 14697133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
